#medtech market

[cetas-healthcare]

Latest Blog: Key Market Research Studies for MedTech Companies

Explore essential market research studies pivotal for new product development in the medical device industry, ensuring strategic success from ideation to commercialization. Dive into our detailed guide on market analysis, customer needs, regulatory compliance, and pricing strategies at Cetas Healthcare.

[healthcareporium]

Decoding Trends and Innovations in the Blood Cancer Diagnostics Industry

Blood cancer, a complex group of diseases affecting the blood, bone marrow, and lymphatic system, demands precise and efficient diagnostic tools. As advancements in medical technology continue to reshape the healthcare landscape, the Blood Cancer Diagnostics Market is witnessing dynamic changes. Let’s explore the key dynamics shaping this market. Advanced Testing Strategies in the Blood Cancer…

[rohitpalan]

MedTech's Promise in Health Behavior Modification

The MedTech market refers to the sector of healthcare that focuses on the development, production, and distribution of medical devices, equipment, and technologies used in the diagnosis, treatment, and monitoring of various medical conditions.

In 2023, the Medtech market is expected to be worth US$ 503,206.0 million. The market is expected to reach US$ 776,467.7 million by 2033, expanding at a 4.4% CAGR throughout the forecast period. The MedTech industry is driven by several factors, empowering patients and increasing access to care.

MedTech has facilitated the development of improved diagnostic instruments and processes that aid in disease identification and diagnosis. High-resolution imaging systems, genetic testing, molecular diagnostics, and point-of-care testing equipment are a few examples. These tools assist clinicians in making educated decisions and providing tailored treatment strategies.

Unlock Insights: Download the Sample Report to Understand Rising Demand for MedTech Market: https://www.futuremarketinsights.com/reports/sample/rep-gb-17559

MedTech has transformed treatment techniques and therapies in a variety of medical professions. Robotic-assisted surgery devices allow for minimally invasive operations, which reduces patient trauma and speeds up recovery. Advanced prosthetics and orthotics make use of robotics and sensor technology to improve mobility and quality of life for those who have lost a limb or have a disability. Furthermore, targeted medication delivery systems and implantable devices are increasing the efficacy and precision of therapies.

Through telemedicine and remote monitoring systems, MedTech has substantially improved access to healthcare. Telemedicine systems enable patients to consult with healthcare specialists over the Internet, decreasing the need for in-person visits, particularly for routine check-ups and follow-ups. Remote monitoring devices and wearable sensors allow for continuous monitoring of vital signs, allowing for early detection of health disorders and proactive intervention.

Key Takeaways from this Market:

The MedTech industry in the United States is predicted to reach US$ 73,468.0 million by 2033, increasing at a 4.1% CAGR.

The MedTech industry in Germany is estimated to reach a market share of US$ 53,037.9 million, expanding at a CAGR of 5.2% by 2033.

During the forecast period, the medtech industry in the UK is expected to reach a market share of US$ 39,602.3 million, securing a 7.1% CAGR.

The MedTech industry in China is predicted to reach US$ 49,364.5 million by 2033, increasing at an 8.7% CAGR.

Japan’s medtech industry is predicted to achieve a market share of US$ 36,130.1 million, rising at a 6.7% CAGR during the forecast period.

With a Market Share of 33.12% from 2022 to 2033, the Hospitals and Clinics segment is expected to dominate the MedTech industry.

With a CAGR of 7.8% from 2022 to 2033, Diagnostic Equipment is expected to dominate the MedTech industry.

Personalized Market Insights: Request Customizations to Make Informed Decisions in this Market: https://www.futuremarketinsights.com/customization-available/rep-gb-17559

How Does the Competition Look in the MedTech Market?

The MedTech market is a worldwide one, with companies attempting to establish a presence in various countries and get access to international markets. Companies must manage a variety of regulatory regimes, reimbursement systems, and market dynamics in their respective markets. It is critical for success to be able to create strong distribution networks and relationships in several nations.

While there is a lot of competition in the medtech market, there is also a lot of room for growth. People are turning to Medtech to help them reach their fitness and wellness objectives as their interest in health and wellness grows. As a result, increased investment in the creation of health coaching applications, as well as mergers and acquisitions as larger competitors strive to consolidate their positions, are inevitable.

Cost factors play a crucial influence in the MedTech market’s competition. Companies must find a happy medium between generating new, high-quality products and maintaining affordability and cost-effectiveness. Gaining a competitive edge requires demonstrating value, such as improved patient outcomes, lower healthcare costs, or increased efficiency.

Consolidation and mergers are being utilized by leading players to fortify their market standing and acquire entry to fresh markets. The sector is experiencing notable expansion in developing economies, especially in nations such as India and China.

Key Players:

Johnson & Johnson

Medtronic

Siemens Healthineers

GE Healthcare

Stryker

Abbott Laboratories

Boston Scientific

BD

Olympus Corporation

Zimmer Biomet

Ask Our Industry Experts to Learn Comprehensively about the Market Share Analysis of Key Players: https://www.futuremarketinsights.com/ask-question/rep-gb-17559

Market Outlook by Categorization:

By Product Type:

Medical Devices

Diagnostic Equipment

Surgical Instruments

Implantable Devices

Monitoring Devices

Others

Medical Equipment

MRI machines

X-ray machines

CT scanners

In-vitro Diagnostics (IVD)

Laboratory-Based Tests

Point-of-Care Tests

Digital Health

Telemedicine Platforms

Health Monitoring Wearables

Mobile Health Applications

Electronic Health Records (EHR) Systems

By Application:

Cardiology

Orthopedics

Oncology

Neurology

Respiratory

Others

By End-user:

Hospitals and Clinics

Ambulatory Surgical Centers

Home Healthcare

Diagnostic Laboratories

By Region:

North America

Latin America

Europe

East Asia

South Asia

Oceania

The Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:         

Future Market Insights Inc. Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware – 19713, USA T: +1-845-579-5705 For Sales Enquiries: sales@futuremarketinsights.com Website: https://www.futuremarketinsights.com LinkedIn| Twitter| Blogs | YouTube

[prismmediawire]

BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts

Company continues to advance its placental-derived product portfolio with the first patent granted in the fenestrated wound care market

POMPANO BEACH, Fla., Nov. 25, 2024 – PRISM MediaWire – BioStem Technologies, Inc.  (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Biostem’s patent application No. 18/591,883 for STERILE HUMAN PLACENTAL ALLOGRAFTS HAVING A PLURALITY OF SLITS, OPENINGS, AND/OR FENESTRATIONS FORMED THEREON. The patent application will grant as U.S. Patent No. 12,144,831 on November 19, 2024.

This patent will be used in the development of novel placental allografts designed for advanced wound care using BioStem’s BioREtain® process, which preserves essential natural factors. The allografts using this technology will feature flaps that open to allow exudate to escape without sacrificing surface area, making them suitable for both acute and chronic wound settings. This technology is unique, as there are no other fenestrated allografts on the market that offer the same benefits.

“BioStem continues to drive innovation in the wound care space, and we are pleased to enhance our intellectual property portfolio with the issuance of this significant patent. This is the first and only patent granted for use in tabular fenestrated allografts, which will support our commercial efforts and expands our IP portfolio. With 27 patents pending and 42 issued, BioStem has a strong portfolio across the wound care landscape that will protect the company as we advance in the market.”

A product using this technology is under development and is currently not commercially available and will be introduced using the HCT/P regulatory pathway. Once developed, the new allografts could be used as a protective covering for exudating wounds across the acute or chronic setting.

Join BioStem’s Distribution List & Social Media: To follow the latest developments at BioStem, sign-up to the Company’s email distribution list HERE , and follow us on Twitter and LinkedIn.

About BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain ® processing method. BioREtain ® has been developed by applying the latest research in advanced wound care, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established per current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap2 ™, VENDAJE ®, VENDAJE AC ®, and VENDAJE OPTIC ®. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida.

For more information visit biostemtechnologies.com and follow us on Twitter and LinkedIn.

Forward-Looking Statements: Except for statements of historical fact, this release also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified using words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements with respect to the operations of the Company, strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact of any changes to the reimbursement levels for the Company’s products; (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company’s products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete;(4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company’s ability to raise funds to expand its business; (6) the Company has incurred significant losses since inception and may incur losses in the future; (7) changes in applicable laws or regulations; (8) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (9) the Company’s ability to maintain production of its products in sufficient quantities to meet demand; and (10) the COVID-19 pandemic and its impact, if any, on the Company’s fiscal condition and results of operations; You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

BioStem Technologies, Inc. Phone: 954-380-8342  Website: http://www.biostemtechnologies.com E-Mail: info@biostemtech.com Twitter: @BSEM_Tech Facebook: BioStemTechnologies

PCG Advisory Jeff Ramson jramson@pcgadvisory.com 646-863-6893 

Source: BioStem Technologies, Inc.

[foxxfin]

Dive into the Medtech Market in Europe with FOXX. Discover key players, emerging trends, and opportunities in the medical technology sector across Europe, empowering your business with valuable insights and analytics.

[market-insider]

Suction Catheters Market Forecast: A Holistic Approach to Market Trends

The global suction catheters market size is expected to reach USD 844.1 million by 2030, based on a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.2% from 2022 to 2030. Suction catheters help in clearing the respiratory tract of ventilator-dependent patients or patients suffering from respiratory disorders. The rise in the number of people suffering from chronic respiratory illness is proliferating the demand for suction catheters. For instance, as per the Irish Thoracic Society, in 2016, there were 643,580 inpatient hospitalizations in Ireland. Out of which, 32% of inpatients were older than 65 years and over. Respiratory diseases accounted for 19.1% of inpatient hospitalizations in Ireland.

Suction Catheters Market Report Highlights

Based on type, the closed suction catheter segment dominated the market in terms of revenue share in 2021. Further, the closed suction catheter segment is expected to witness the fastest growth rate of 8.8% over the forecast period, owing to a rise in cases of cross-contamination

Based on material, the latex-free segment dominated the market with a share of 69.7% in 2021, owing to the increased use of silicon-based catheters by healthcare professionals. Further, the latex-free segment is expected to grow at the fastest CAGR of over 8.8% during the forecast period

Based on end use, the hospital segment held the majority of the market share in terms of revenue in 2021. On the other hand, the ambulatory care centers segment is expected to witness the fastest growth of 10.9% during the forecast period

In 2021, North America dominated the market with a share of around 45% owing to the rising prevalence of various types of chronic diseases and the growing demand for respiratory devices. The Asia Pacific suction catheters market is expected to expand at the fastest rate of 8.6% during the forecast period. The growth can be attributed to the rise in the aging population and the increasing prevalence of chronic diseases

For More Details or Sample Copy please visit link @: Suction Catheters Market Report

The Covid-19 pandemic has highlighted the importance of respiratory medical devices owing to the rise in the number of ventilator-supported patients during the pandemic. In addition, factors such as rising cases of chronic diseases, and an increase in pollution levels are also contributing to heightened demand for suction catheters. In March 2020, U.S. Food and Drug Administration (FDA), granted emergency approval for Vesper, a device developed by Prisma Health that supports patients on ventilators.

In addition, during the pandemic, several governments across the globe and healthcare companies were improving medical treatment to treat patients suffering from Covid-19 patients. This in turn increased the use of catheters in emergency clinics and hospitals during the pandemic thereby positively impacting the demand for suction catheters. The rise in investments by the government and players to improve the healthcare industry is also boosting the demand for suction catheters. For instance, as per UK Government, close to 10,000 ventilators were added to the stock. Additionally, Rolls Royce, Ford, and Honda in the UK started manufacturing ventilators to cope with the increasing demand due to the COVID-19 outbreak.

[sraotrading]

(via साक्षी मेडटेक एंड पैनल्स आईपीओ समीक्षा 2023 - जीएमपी, मूल्य, विवरण) साक्षी मेडटेक एंड पैनल्स आईपीओ समीक्षा: साक्षी मेडटेक एंड पैनल्स लिमिटेड (Saakshi Medtech and Panels Limited) अपना आईपीओ लेकर आ रही है। यह एक एसएमई आईपीओ है, जो कुल मिलाकर 45.16 करोड़ रुपए तक है। कंपनी को एनएसई एसएमई पर लिस्टिंग किया जायेगा।आईपीओ के सदस्यता के लिए खुलने की तारीख 25 सितंबर, 2023 रहेगी और बंद होने की तारीख 27 सितंबर, 2023 रहेगी।

[duenorthsearch]

DUE NORTH EXECUTIVE SEARCH - Marketing Recruiters

Due North Executive Search is a top-tier executive search firm based in Minneapolis. Our team of experienced recruiters specializes in marketing executive positions and is highly knowledgeable of the local market. We provide personalized services to our clients and take the time to understand their needs. Our commitment to excellence and dedication to each search has resulted in successful placements and satisfied customers. Contact us today to learn more about our services.

Visit - https://www.duenorthsearch.com/ Phone - +1 (833) 383-6678 Address - 9974 Urbandale Ln N , Maple Grove , MN , United States

[healthcareporium]

Unlocking the Potential: Emerging Players in Blood Cancer Diagnostics

Blood cancer, a complex group of diseases affecting the blood, bone marrow, and lymphatic system, demands precise and efficient diagnostic tools. As advancements in medical technology continue to reshape the healthcare landscape, the Blood Cancer Diagnostics Market is witnessing dynamic changes. Let’s explore the key dynamics shaping this market. Advanced Testing Strategies in the Blood Cancer…

[chevvy-yates]

MILITECH MEDS/STIMS THYJS TOOK DURING SERVICE:

Not so long ago I sat down and thought about which drugs/stims Thyjs had to make use of during his career and service at Militech EU/Benelux Union/KCT, researching the CP lore about said stuff and thought I should make a post with it here as well since I've only posted it in discord. Maybe some of you are intersted in it as well.

Beware it's a lot of text (as always).

FYI: I headcanon that Militech EU/Benelux Union in 2077 has developed forward in topics of developing combat drugs for their soldiers. In the past to benefit in operations/wars the military gave their soldiers experimental drugs that made the soldiers highly psychologically addictive to them, often resulting in them getting cyberpsychosis. I also headcanon it might still be common in the NUSA but for EU Militech is a bit different: so Thyjs was being watched and cared for as Militech and especially Netherland’s Royal Army/KCT saw a huge value in their special force soldiers so they did everything to prevent especially cyberpsychosis. That being said, Thyjs received high treatment after each operation, depending on how nerve wracking and physically draining it has been for him and how often he had to make use of said drugs of the following list:

|

Militech Combat Drugs

These drugs are highly illegal on the market and only restricted quantities are available to the NUSA military (and Militech Mercs). It’s known that Militech has made these combat drugs available to any military force in the world that can meet their price. It would be extremely difficult for any normal (non-military) person to obtain these drugs legally. A near impossible streetwise check or a very difficult streetdeal check could be made to obtain a single dose of one of these drugs at triple the cost.

///Prime¹

This drug narrows the user’s concentration down to a highly focused point and eliminates extraneous emotion, making the user extremely cold and rational. An average testing of the user’s vitals should be made when the drug wears off. Failure indicates that the user has not made a successful transition to an unprimed state. The user is distracted and finds it difficult to concentrate. Increases; enhanced perception Benefits; better awareness/notic Duration; up to 24h Side Effects; possible lack of Concentration after wearing off ———

This is the drug I imagine Thyjs must have taken the most if not almost daily during active service (does not include off duty), so it explains why he lost emotions. He might have experienced a need/mild addiction for taking them each day due to the lack of concentration setting in when having time off his duty. He is more or less forced to discontinue taking them when he runs out of his packages/doses left he took with him on the NUSA job. Without them he will experience a huge loss of concentration in the first weeks, which is why he will get distracted by daily life noises in Nighty City when he doesn’t use them anymore. His medtech will prescribe him something else for lack of concentration, that does not result in addictiveness as Thyjs does not have access to Militech drugs anymore since he’s officially announced as deceased. They will help him with his concentration while he tries to get used to daily life. Chance is high he has to take them life long.

//////

///Timewarp¹

Timewarp sharpens the reflexes of the user and enhances reaction time to an inhuman level. After a dose of Timewarp wears off, the user should make a difficult entire body and cyberware check. Failure indicates that the character takes damage from body overstress. Increases; reaction time and stamina, (headcanon; increases Thyjs’ fastness with Sandevistan as in he can ‘warp’ more times than usual) Benefits; inhuman reflexes Duration; 2-3h Side Effects; no feel of hunger and thirst, possible internal bleeding after wearing off ———

This is the drug I imagine Thyjs did made use of when he needed his Sandevistan to be active more than usual. It’s not recommended to take it often as it causes internal bleeding as he overstresses his entire body with it due to making him super fast (why you experience he’s warping). He was carefully instructed with the usage of it and is aware of the side effects. He had to make frequent use of it in the past though, so after that he was strictly ordered to rest for weeks including difficult check ups in nearby Militech hospitals to be sure he didn’t take any damage from it, while they also especially checked and repaired his Sandevistan cyberware as it also took damage by being overused. He experienced numbness in his extremities while his Sandevistan took damage as it replaced his entire spine (yes it’s not just placed over and connected to his spine, it’s a 100% cyberware replacement).

|

Trauma Drugs

Manufactured and distributed by Trauma Team International, these trauma drugs are designed to meet the needs of any field medic. No good medtech would be caught without them. Available in liquid form for use in air hypos or as a single dose slap patch. These drugs are legally available to licensed medical personnel. They can also be obtained illegally with an average streetdeal check or a difficult streetwise check. If obtained illegally, prices are doubled

///Surge¹

This drug acts like endorphins. The patient receives a burst of energy and can ignore the need for food and sleep and receives endurance and more strength. The patient's stats will be halved after the drug wears off until he receives at least five hours of sleep. Increases; endurance, allowing the user to stay alert for longer periods Benefits; potent painkiller; wound level is treated as if less Duration; 3-4h Side Effects; feeling weak/powered out, chance of mental delusions ——

///Trauma¹

This drug is administered when the patient is in a mortal wound state. For the duration of the drug, death saves are three times easier. This drug is usually applied by non-medical personnel or even the patient himself since stabilization is always a better course of action. Benefits; potent painkiller; less loss of blood Duration; 6-8h Side Effects; loss of consciousness, mental delusions ———

Thyjs is not a field medic but he was of course educated in first aid and constantly took lessons to refresh his knowledge and the utilization in case the medic would not be near so he could help either himself or a mate until the medic of his platoon arrived. Therefore every soldier was given some Trauma drugs in their kit they had to carry on their belt.

|

Lazarus Combat Drugs

Officially, Lazarus will neither confirm nor deny the use of combat drugs by its troops. It is, however, widely rumored to be a common practice among mercenary corporations. Two drugs in particular have been associated with Lazarus troops: The first is Dialacopamine (also known as Spotlight). The other is a 'dorph and aggressiveness booster made by Sturm-Schaller SA in Germany, called Lapazole LM (known on the streets as HappyKill), which is a lethal combat drug, dangerous and addictive (Thyjs didn’t get this). HappyKill was tested on Lazarus troops for a while, then discarded as too dangerous. There is a black market among the troops, and it still pops up from time to time.

///Dialacopamine a.k.a. Spotlight²

A fairly benign awareness heightening drug, produced by Biotechnica, known on the streets as Spotlight. It is popular with special ops troops on infiltration and ambush missions. Increases; wareness skills Duration; 5h Side Effects; repeated use includes a 50% chance of psychological addiction and a 10% chance of nerve degeneration per dose after the 5th usage. ———

Now this is not exactly a Militech drug, yet it is a combat drug used by special ops troops, so I can imagine Thyjs may have used a similar one at least one time (maybe even twice) during high risk spec op missions executed by KCT. I read the ‘per dose after the 5th usage’ as in: you take it a fifth time it definitely causes addiction. So I conclude Thyjs’ entire squad was instructed about the risk of taking this drug so none of them would be allowed to take it more than three times during their service and if they took it they needed to report it including what they experienced. This was a safety measurement to prevent addiction and up for debating if the soldier could continue or not (ofc there have been cases in the past where soldiers fell into addiction). I also do headcanon once you are in KCT, the chance is high you quit after a few operations — either because you make it out barely alive or because it fucks with you ptsd-wise and in general KCT only accepts the fittest and youngest soldiers in their ranks, both mentally and bodily, so Thyjs would have also only have been in service for a bunch of years (at the time he’s in NUSA he was still an active member, already having served since 2074 which would make it about 4 years in 2078 and that would probably have been his last year).

¹ Source: Cyberpunk 2020 – Chromebook 3, Pharmaceuticals, Page 17 ² Source: Cyberpunk 2020 – Corporation Report 2020 2 Lazarus/Militech

[medtech-mara]

Welcome to my new series of posts about Cyberpunk RED source material! This time we will be putting the CYBER into the PUNK by discussing everything Cyberware.

Today, though we must start with the basics, I wanted to just show the catalog and let you go on our own way, but I felt it was best to open the discussion. I am willing to answer your questions should you have some in the event you want to roleplaying/write accordingly when Phantom Liberty releases.

Welcome to Blue Remedies Health Clinic, My name is Mara Sterling, and I will be your Ripperdoc today? Have you ever used a Ripperdoc before? I notice you don't have any cyberware at all? Nervous? Don't be! We'll go walk through this together.

What is Cyberware?

Cybertechnology can be purchased almost anywhere. Some of the medical procedures are simple: walk-in types of surgery with minor installations taking place in whatever shopping mall clinics(Bodyshoppe, Fashion/Fusion, and Parts N' Programs are three popular chain stores) still exist, or drop-in medical centers (Docs R Us™... or my clinic Blue Remedies Health Clinic in the Wellsprings) These installations are much like getting your ears pierced. You can even have upgrades and improvements plugged into the old hardware for the cost of the new parts, allowing you to start small (called "stripped" or "economy") and add as you go. It is IMPORTANT to note that you CANNOT install cyberware to a critical injury, it has to heal first.

Where can I get my Cyberware installed?

Any Ripper doc if you are brave enough... Joking aside.. Depending on what cyberware you are wanting to install, depends on where you'd likely go. Don't worry I can guide you through this process with telling you where you'd likely get this cybernetic installed. Mall: means you can literally get the installation done in any mall or street corner bio-mod shop; the equivalent of ear-piercing in the 1900s. There are not as many of these as there were in the 2020s. Clinic: means an actual Medtech in a medical surgery clinic. Most of the installation is automated, but it takes a skilled practitioner to use that gear. Most ripperdocs are at this level. Hospital: means the work requires major surgery and a Medtech capable of doing this kind of work. This also requires a full hospital or the nearest equivalent, which is relatively rare. *Benefits from multiple installations of the same cyberware do not stack unless otherwise noted

"I was thinking about getting a a Sigma frame like Panthera, OH or have a dart eye like Optic from Night Raid! That's so cool!"

Unfortunately, there are prerequisites for some cyberware. Rome wasn't built in a night nor was David Martinez, so you will need to build yourself up to such an upgrade as an exo-skeleton like the Sigma frame, but I can't recommend one enough.

How is there such a thing as too much Cyberware?

Besides the obvious answer if you want to see God under the boot of some Maxtac lapdog? then yes. There are limits on how many cyberware slots your body can have. There will be a display how many slots can be used per cyberware type.

Cyberware types? You mean there are more than 2? I thought it was just cyberlimbs or Kiroshis?

There are 8 types of cybernetics available to the open market. However, your Ripperdoc MAY or MAY NOT have special types of cyberware they've crafted themselves, it never hurts to ask. Currently Avaliable: Fashionware, Neuralware, Cyberoptics, Cyberaudio, Internal Body Cyberware, External Body Cyberware, Cyberlimbs, & Borgware (my personal favorite, but watch out!)

Cool, I've picked out what I wanted, lets get started?

Whoa, hold on, choombatta, you picked some heavy hitters there, do you think you can handle it? If you've recently suffered from major traumas, I like to suggest meeting with a therapist first, your humanity is something to treasure and you won't get very far without it... Well unless you are Adam Smasher, were you born with 0 empathy?

Humanity? Therapy? What's all this GONKED shit?

Each cybernetic you install will cost a bit of your humanity, you are giving up some of your human self in place of machine, that doesn't come free. Fortunate for you, therapy does wonders, it can often help you discern what is the psychosis speaking or you, but without it, I'm sure you won't last 6 months on the street before C-Swat comes for you. It's always recommended that if you install heavy cyberware to see your therapist after. It's also a good idea to see your therapist after any traumatic event that has happened to or if front of you. It's not just the cyberware that eat at your humanity.

Annnnnd that's all for this post! Next post we will start going over some actual cyberware, starting with a personal favorite, Fashionware! I really hope to see some of the work you guys make with the new DLC coming out, and armed with this new knowledge about cyberware and cyberpsychosis (soon™)

[max1461]

Hank is of course correct to say to the executives at Danaher and Cepheid "we are not enemies here, we're allies, and the enemy is Tuberculosis" even though that is not true, and maybe he even knows it's not true. The executives at these companies, as at all medtech companies, are in a very real sense enemies of all mankind. But it's good to appeal to them on your large public platform; it's good to make an implicit threat.

A few months ago, John made a video addressing Johnson & Johnson, saying that it would be a good business decision for them on PR grounds (implicit: I, John Green, with my large platform, am going to make this a good business decision for you on PR grounds) to make generic variants of bedaquiline available sooner in more countries. Evidently he had enough leverage to make this true, and so generic variants of bedaquiline will now become available in certain countries with high TB rates and a very large number of lives will probably be saved.

Hank is attempting to do the same thing here. I do not know if he has the leverage to make it work, but I assume that he and John have talked about it and they think that they do. Let's hope they do.

Saying "we are not enemies, we have a common enemy, etc. etc" appeals to the humanity of the decision makers at these companies, which presumably they do have and which against the selective pressures of the market might possibly still factor into their decision somewhere, it appeals to the humanity of e.g. the engineers at these companies, who might be able to put some kind of pressure up the chain towards the right decision getting made (and they have much less of a vested interest against it), and it is a wonderfully cordial way to make an implicit PR threat, that puts you on great rhetorical ground.

This is good propaganda, targeted and thought-through propaganda, that stands a reasonable chance of making the world a better place in a measurable way. Sometimes it's good to say things you don't mean, or that aren't true, or both. Sometimes even when all intelligent observers kinda know they aren't true.